Some people carry APOE ε4 — the strongest common genetic risk factor for Alzheimer's — yet never develop the disease. Columbia University researchers have now found out why: a rare protective mutation in the FN1 gene limits fibronectin buildup around brain blood vessels, preserving the blood-brain barrier. The findings, published in Nature Aging, open a promising new path toward Alzheimer's prevention therapies.
Some people carry APOE ε4 — the strongest common genetic risk factor for Alzheimer's disease — yet remain mentally sharp well into their 80s. Researchers at Columbia University have now uncovered a key reason why: a rare protective mutation in the fibronectin (FN1) gene that limits harmful protein buildup around the brain's blood vessels, preserving a critical defense system known as the blood-brain barrier.
Published in Nature Aging, the study reveals that APOE ε4 drives excessive accumulation of fibronectin around brain blood vessels, which disrupts communication between support cells and blood vessel cells through abnormal integrin and focal adhesion kinase signaling. This derails a network of growth factors (VEGF, HBEGF, IGF1) that normally keep the blood-brain barrier intact — making the brain more vulnerable to damage. The rare FN1 mutation appears to blunt this cascade, and similar biological patterns were confirmed in human brain tissue and cerebrospinal fluid samples.
Key Takeaways:
Why it matters: Rather than waiting to treat Alzheimer's after damage has set in, this research points toward reproducing a natural genetic defense — potentially allowing clinicians to intervene early, before significant neurological harm occurs.
